Q2 2025 AxoGen Inc Earnings Call Transcript
Key Points
- Axogen Inc (AXGN) reported strong revenue growth of 18.3% in Q2 2025, reaching $56.7 million, driven by double-digit growth across all nerve repair target markets.
- The company achieved a gross margin of 74.2%, an improvement from 73.8% in the same period last year, due to lower inventory write-offs and shipping costs.
- Axogen Inc (AXGN) is on track with its Biologics License Application (BLA) for Avance Nerve Graft, expecting approval in September 2025, which will secure 12 years of market exclusivity.
- The company has expanded its commercial infrastructure, with significant hiring in breast resensation and other high-potential territories, supporting broader adoption of its products.
- Axogen Inc (AXGN) has seen significant external validation with 17 new peer-reviewed publications citing clinical use or discussion of its products, enhancing its reputation in peripheral nerve repair.
- Operating expenses increased to $40.3 million, up from $35.8 million in the second quarter of 2024, although as a percentage of revenue, they decreased by 3.5%.
- The gross margin for the first half of 2025 was 73.1%, which is 3% less than the first half of 2024, primarily due to increased product costs related to the transition of processing Avance Nerve Graft.
- The company faces potential logistical challenges post-BLA approval, particularly concerning the supply of trunk stock for unplanned procedures.
- Despite progress, Axogen Inc (AXGN) still has a significant portion of its accounts that are not classified as high-potential, indicating room for improvement in customer engagement.
- The company anticipates that the BLA approval process may impact Q3 2025 gross margins due to costs related to the transition to processing as a biologic.
(audio in progress)
Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Lindsey Hartley, Chief Financial Officer. Michael will discuss second quarter 2025 financial results and corporate highlights. Lindsey will then provide details on financial performance, guidance, and overall outlook for the year. This will be followed by a question-and-answer session.
Today's call is being broadcast live via webcast, which is available on the Investors section of Axogen's website. Following the end of the live call, a replay will be available in the investors section of the company's website at www.axogeninc.com.
Before we get started, I'd like to remind you that during the conference call, the company will make projections and forward-looking statements. Forward-looking statements, which are usually identified by the use of words such as objectives, targets, will, believe, expect, estimate, should, guidance, intend, projects, or other similar phrases, include, but are not limited
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
